Abstract:Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG recurrence and progression. In this study, the transcriptome characteristics of four groups, namely, normal brain tissue and recurrent LGG (rLGG), normal brain tissue and secondary glioblastoma (sGBM), primary LGG (pLGG) and rLGG, and pLGG and sGBM, were compared using Chinese Glioma Genome Atlas (CGGA) and Genotype-Tissue Expression Project (GTEx) databases. In this study, 296 downregulated and 396 upregulated differentially expressed genes (DEGs) with high consensus were screened out. Univariate Cox regression analysis of data from The Cancer Genome Atlas (TCGA) yielded 86 prognostically relevant DEGs; a prognostic prediction model based on five key genes (HOXA1, KIF18A, FAM133A, HGF, and MN1) was established using the least absolute shrinkage and selection operator (LASSO) regression dimensionality reduction and multivariate Cox regression analysis. LGG was divided into high- and low-risk groups using this prediction model. Gene Set Enrichment Analysis (GSEA) revealed that signaling pathway differences in the high- and low-risk groups were mainly seen in tumor immune regulation and DNA damage-related cell cycle checkpoints. Furthermore, the infiltration of immune cells in the high- and low-risk groups was analyzed, which indicated a stronger infiltration of immune cells in the high-risk group than that in the low-risk group, suggesting that an immune microenvironment more conducive to tumor growth emerged due to the interaction between tumor and immune cells. The tumor mutational burden and tumor methylation burden in the high- and low-risk groups were also analyzed, which indicated higher gene mutation burden and lower DNA methylation level in the high-risk group, suggesting that with the accumulation of genomic mutations and epigenetic changes, tumor cells continued to evolve and led to the progression of LGG to HGG. Finally, the value of potential therapeutic targets for the five key genes was analyzed, and findings demonstrated that KIF18A was the gene most likely to be a potential therapeutic target. In conclusion, the prediction model based on these five key genes can better identify the high- and low-risk groups of LGG and lay a solid foundation for evaluating the risk of LGG recurrence and malignant progression.

STAT3 drives the malignant progression of low-grade gliomas through modulating the expression of STAT1, FOXO1, and MYC

Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma

Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.

Expression and survival analysis of the STAT gene family in diffuse gliomas using integrated bioinformatics

Expression and Significance of STAT3 and CyclinD1 in Human Neuroglioma

STAT3 is a Biologically Relevant Therapeutic Target in H3K27M-mutant Diffuse Midline Glioma

Knockdown of STAT3 Expression by RNAi Suppresses Growth and Induces Apoptosis and Differentiation in Glioblastoma Stem Cells.

The role of STAT3 activation in modulating the immune microenvironment of GBM

STAT3 Signaling Pathway Regulates Glioma Stem Cells Induced Host Macrophage Malignance

Targeting Stat3 Suppresses Growth of U251 Cell-Derived Tumours in Nude Mice

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

Abstract 2099: FoxM1 Drives a Feed-Forward STAT3-activation Signaling Loop to Promote the Self-Renewal and Tumorigenicity of Glioblastoma Stem Cells

Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway

STAT3 Signal Transduction Pathway and Methods for Tumor Therapy

STAT5A Induced LINC01198 Promotes Proliferation of Glioma Cells Through Stabilizing DGCR8

TGF-β Signaling-Related Signature for Predicting Prognosis and Therapeutic Response in Lower-Grade Glioma

SH2B3, Transcribed by STAT1, Promotes Glioblastoma Progression Through Transducing IL-6/gp130 Signaling to Activate STAT3 Signaling

RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma